Ensysce Biosciences (ENSC) Total Non-Current Liabilities (2018 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Total Non-Current Liabilities of $35.0 for Q3 2025, down 98.91% year-over-year from $3213.0 in Q3 2024, and down 96.61% quarter-over-quarter from $1033.0 in Q2 2025.
Ensysce Biosciences (ENSC) Total Non-Current Liabilities (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Total Non-Current Liabilities for 8 consecutive years, with $35.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Total Non-Current Liabilities fell 98.91% year-over-year to $35.0; the TTM figure through Sep 2025 stood at $35.0 (down 98.91% YoY), while the FY2024 annual figure was $10096.0, down 61.74% from the prior year.
- Total Non-Current Liabilities retreated to $35.0 in Q3 2025 per ENSC's latest filing, from $1033.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $8.4 million in Q2 2022 and bottomed at $35.0 in Q3 2025.
- Historically, Total Non-Current Liabilities has averaged $1.6 million across 5 years, with a median of $69507.0 in 2023.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities jumped 978.83% — and 2023, when it plunged 99.43%.
- Ensysce Biosciences' Total Non-Current Liabilities stood at $8.1 million in 2021, then slumped by 94.43% to $450494.0 in 2022, then tumbled by 94.14% to $26388.0 in 2023, then slumped by 61.74% to $10096.0 in 2024, then sank by 99.65% to $35.0 in 2025.
- Business Quant data shows ENSC's Total Non-Current Liabilities at $35.0 in Q3 2025, $1033.0 in Q2 2025, and $130180.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Ensysce Biosciences | 960,039.34 | -3.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 35.00 |
| Jun 30, 2025 | 1,033.00 |
| Mar 31, 2025 | 130,180.00 |
| Dec 31, 2024 | 10,096.00 |
| Sep 30, 2024 | 3,213.00 |
| Jun 30, 2024 | 9,615.00 |
| Mar 31, 2024 | 17,433.00 |
| Dec 31, 2023 | 26,388.00 |
| Sep 30, 2023 | 30,473.00 |
| Jun 30, 2023 | 47,696.00 |
| Mar 31, 2023 | 91,318.00 |
| Dec 31, 2022 | 450,494.00 |
| Sep 30, 2022 | 2.80 Mn |
| Jun 30, 2022 | 8.39 Mn |
| Mar 31, 2022 | 2.46 Mn |
| Dec 31, 2021 | 8.09 Mn |
| Sep 30, 2021 | 3.07 Mn |
| Mar 31, 2021 | 2.78 Mn |
| Dec 31, 2020 | 750,234.00 |
| Dec 31, 2019 | 10.34 Mn |